Jason Gabelman, an analyst from TD Cowen, reiterated the Buy rating on Celcuity. The associated price target is $190.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jason Gabelman has given his Buy rating due to a combination of factors related to Celcuity’s clinical and commercial prospects, valuation, and risk‑reward profile. He likely sees the company’s lead programs and trial designs as well positioned within their target indications, with data to date supporting a differentiated mechanism of action and potential for meaningful clinical benefit relative to existing standards of care.
In addition, Gabelman appears to view the current share price as not fully reflecting Celcuity’s long‑term revenue and pipeline optionality, creating upside if upcoming milestones are met. He also seems to believe that the company’s balance sheet, access to capital, and partnership or strategic optionality are adequate to support development plans, making the stock attractive on a risk‑adjusted basis at this stage.
Gabelman covers the Energy sector, focusing on stocks such as BP, Chevron, and Cheniere Energy. According to TipRanks, Gabelman has an average return of 12.3% and a 64.58% success rate on recommended stocks.
In another report released on March 10, Needham also assigned a Buy rating to the stock with a $122.00 price target.